Avita Medical (RCEL) Stock Price, News & Analysis

Company Overview

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.

Key Stats

• Today's Range: $5.31 to $5.53
• 50-Day Range: $4.77 to $10.25
• 52-Week Range: $4.71 to $14.16
• Volume: 212,465 shs
• Average Volume: 187,874 shs
• Market Capitalization: $145.76 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $16.50
• Consensus Rating: Moderate Buy

Avita Medical Stock Analysis - MarketRank™

Avita Medical scored higher than 17% of companies evaluated by MarketBeat, and ranked 852nd out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Avita Medical has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Avita Medical has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Avita Medical are expected to grow in the coming year, from ($0.95) to ($0.04) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Avita Medical is -2.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Avita Medical is -2.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Avita Medical has a P/B Ratio of 32.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

18.29% of the float of Avita Medical has been sold short.

Short Interest Ratio / Days to Cover

Avita Medical has a short interest ratio ("days to cover") of 17, which indicates bearish sentiment.

Change versus previous month

Short interest in Avita Medical has recently increased by 13.38%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Avita Medical does not currently pay a dividend.

Dividend Growth

Avita Medical does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

18.29% of the float of Avita Medical has been sold short.

Short Interest Ratio / Days to Cover

Avita Medical has a short interest ratio ("days to cover") of 17, which indicates bearish sentiment.

Change versus previous month

Short interest in Avita Medical has recently increased by 13.38%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Avita Medical this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for RCEL on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Avita Medical insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.80% of the stock of Avita Medical is held by insiders.

Percentage Held by Institutions

Only 27.66% of the stock of Avita Medical is held by institutions.

RCEL Stock Analysis - Frequently Asked Questions

How have RCEL shares performed this year?

Avita Medical's stock was trading at $12.80 at the beginning of 2025. Since then, RCEL stock has decreased by 56.9% and is now trading at $5.5150.

How were Avita Medical's earnings last quarter?

Avita Medical Inc. (NASDAQ:RCEL) announced its quarterly earnings data on Thursday, May, 8th. The company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.39) by $0.14. The business earned $18.51 million during the quarter, compared to analysts' expectations of $33.15 million. Avita Medical had a negative net margin of 79.61% and a negative trailing twelve-month return on equity of 632.62%.
Read the conference call transcript.

How do I buy shares of Avita Medical?

Shares of RCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Avita Medical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Avita Medical investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD) and Tesla (TSLA).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/06/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:RCEL
• CIK: 1762303
• Web: www.avitamedical.com
• Phone: (833) 462-8482
• Fax: N/A
• Employees: 130
• Year Founded: 2008

Price Target and Rating

• Average Stock Price Target: $16.50
• High Stock Price Target: $21.00
• Low Stock Price Target: $12.00
• Potential Upside/Downside: +199.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.19)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$61.85 million
• Net Margins: -79.61%
• Pretax Margin: -79.56%
• Return on Equity: -632.62%
• Return on Assets: -71.72%

Debt

• Debt-to-Equity Ratio: 9.39
• Current Ratio: 2.09
• Quick Ratio: 1.72

Sales & Book Value

• Annual Sales: $64.25 million
• Price / Sales: 2.27
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.17 per share
• Price / Book: 32.44

Miscellaneous

• Outstanding Shares: 26,430,000
• Free Float: 25,695,000
• Market Cap: $145.76 million
• Optionable: Optionable
• Beta: 1.52